Business
Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic Value
New Taipei City, Taiwan, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced updated statistical analyses for key blood biochemical markers from
About this update from Jyong Biotech Ltd.
[{"type":"image","alt":"Jyong Biotech Ltd.","displaySize":"","headline":null,"caption":"Jyong Biotech Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":250,"height":81,"url":"https://media.zenfs.com/en/globenewswire.com/4d02bf8bdf07c2a180b8d0cc11d0b5eb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9sIWe9gFz6QoQIjdTMRrYw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/4d02bf8bdf07c2a180b8d0cc11d0b5eb","width":250,"height":81}},"lazy":false},{"type":"text","content":"New Taipei City, Taiwan, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced updated statistical analyses for key blood biochemical markers from its Phase II clinical trial of MCS-8 (PCP) conducted in Taiwan. The results underscore MCS-8’s previously indicated multifaceted clinical and commercial potential beyond its clinical evidence in prostate cancer prevention, showing its potential in helping alleviate high-grade malignancy risk. The data reveals significant new value in metabolic indicators, specifically cholesterol and lactate dehydrogenase (LDH). Building on this momentum, the Company is evaluating the feasibility of expanding MCS-8’s indications to include lipid management, atherosclerosis, and cardiovascular diseases—a strategic move aimed at extending the product’s lifecycle and significantly capturing a broader market share.","length":1203,"tagName":"p"},{"type":"text","content":"The Phase II clinical trial demonstrated that after two years of treatment, subjects receiving MCS-8 showed improved lipid control compared with baseline, including:","length":165,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"A statistically significant reduction in total cholesterol levels (P = 0.036);","length":78,"tagName":"p"}]},{"val":[{"type":"text","content":"A statistically significant increase in serum lactate dehydrogenase (LDH) levels observed in the placebo group (P = 0.024), while no such increase was observed in the MCS-8 group.","length...